Research Use Only
This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.
Tesamorelin
Growth Hormone / IGF-1 AxisFDA ApprovedAlso known as: Tesa, TH9507
Tesamorelin is a synthetic stabilized GHRH analog FDA-approved (as Egrifta) for reducing excess abdominal fat (lipodystrophy) in HIV-infected patients on antiretroviral therapy. It contains the full 44-amino acid sequence of GHRH with a trans-3-hexenoic acid group attached to the N-terminus for enhanced stability.
Overview
Key Takeaways
- →Visceral fat reduction
- →Body composition
- →Cognitive function
- →Half-life: 26–38 minutes
At A Glance
Tesamorelin binds the pituitary GHRH receptor with high affinity due to its trans-3-hexenoic acid modification, which protects the N-terminus from cleavage by dipeptidyl peptidase IV. It stimulates pulsatile GH release that specifically reduces visceral adipose tissue (VAT) through enhanced lipolysis in deep abdominal fat depots. Clinical trials show 15–20% reduction in visceral fat over 26 weeks. Cognitive research suggests GH/IGF-1 signaling in the hippocampus may support memory function in aging adults.
Tesamorelin binds the pituitary GHRH receptor with high affinity due to its trans-3-hexenoic acid modification, which protects the N-terminus from cleavage by dipeptidyl peptidase IV. It stimulates pulsatile GH release that specifically reduces visceral adipose tissue (VAT) through enhanced lipolysis in deep abdominal fat depots. Clinical trials show 15–20% reduction in visceral fat over 26 weeks. Cognitive research suggests GH/IGF-1 signaling in the hippocampus may support memory function in aging adults.
Overview
Tesamorelin is a synthetic stabilized GHRH analog FDA-approved (as Egrifta) for reducing excess abdominal fat (lipodystrophy) in HIV-infected patients on antiretroviral therapy. It contains the full 44-amino acid sequence of GHRH with a trans-3-hexenoic acid group attached to the N-terminus for enhanced stability. Research also explores its benefits for cognitive function and metabolic health in aging.
Potential Benefits
Potential Research Fields
Chemical Information
IUPAC Name
trans-3-hexenoyl-GHRH(1-44)amide
CAS Number
218949-48-5
Molecular Formula
C221H366N72O67S
Molecular Mass
5135.8 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Create a free account to:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
Join 2,800+ researchers
Research
Unlock Research Data
Create a free account to:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
Join 2,800+ researchers
Interactions
Interaction Matrix
Contraindications
Active cancer or history of malignancy. Pituitary surgery or radiation. Pregnancy or breastfeeding. Hypersensitivity to tesamorelin or mannitol.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$45.00
up to $90.00
$5.3327
5
9
vial
Price History
2 data pointsRelated Compounds
View AllCJC-1295 (Mod GRF 1-29)
Growth Hormone / IGF-1 Axis
CJC-1295 without DAC (Modified GRF 1-29) is a synthetic 29-amino acid GHRH analog with four amino acid substitutions that extend its half-life from under 2 minutes to approximately 30 minutes.
CJC-1295 with DAC
Growth Hormone / IGF-1 Axis
CJC-1295 with DAC uses a Drug Affinity Complex linker (maleimidopropionic acid) that forms a permanent covalent bond with serum albumin after injection, extending the half-life to 6–8 days.
GHRP-2
Growth Hormone / IGF-1 Axis
GHRP-2 is a synthetic hexapeptide growth hormone-releasing peptide that potently stimulates GH release from the pituitary gland.
GHRP-6
Growth Hormone / IGF-1 Axis
GHRP-6 is a synthetic hexapeptide growth hormone secretagogue and one of the original GHRPs studied.
Hexarelin
Growth Hormone / IGF-1 Axis
Hexarelin is a synthetic hexapeptide growth hormone secretagogue that produces the most potent GH release of any GHRP.
IGF-1 LR3
Growth Hormone / IGF-1 Axis
IGF-1 LR3 (Long R3 IGF-1) is a modified analog of insulin-like growth factor 1 featuring an arginine substitution at position 3 and a 13-amino acid N-terminal extension.
View Full Dosage Guide →
Protocols, calculator & safety for Tesamorelin
Research Score
8 PubMed studies
Quality Indicators
Data Completeness
100%COA Verification
10
Verified COAs
2
Vendors w/ COA
High verification rate (83%)
Latest test: 3/1/2026
Research Credibility
Limited research available
Quick Facts
Half-Life
26–38 minutes
Molecular Weight
5135.8 g/mol
Administration
Subcutaneous
CAS Number
218949-48-5
Trial Phase
FDA Approved
Safety Profile
Low RiskCommon Side Effects
- • Injection site reactions
- • Fluid retention
- • Arthralgias
- • Myalgias
Stop Use If
- Active malignancy
- Pregnancy
- Pituitary surgery or radiation history
- Acute illness
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Tesamorelin used for in research?
Tesamorelin is a synthetic stabilized GHRH analog FDA-approved (as Egrifta) for reducing excess abdominal fat (lipodystrophy) in HIV-infected patients on antiretroviral therapy. It contains the full 44-amino acid sequence of GHRH with a trans-3-hexenoic acid group attached to the N-terminus for enhanced stability. Research also explores its benefits for cognitive function and metabolic health in aging.
What forms does Tesamorelin come in?
Tesamorelin is available in vial form.
How much does Tesamorelin cost?
Prices start at $45.00 across 5 verified vendors.
How do I compare Tesamorelin vendors?
Compare prices, payment methods, shipping, and COA scores across 5 vendors.
Research Tools
Related Compounds
View AllCJC-1295 (Mod GRF 1-29)
Growth Hormone / IGF-1 Axis
CJC-1295 without DAC (Modified GRF 1-29) is a synthetic 29-amino acid GHRH analog with four amino acid substitutions that extend its half-life from under 2 minutes to approximately 30 minutes.
CJC-1295 with DAC
Growth Hormone / IGF-1 Axis
CJC-1295 with DAC uses a Drug Affinity Complex linker (maleimidopropionic acid) that forms a permanent covalent bond with serum albumin after injection, extending the half-life to 6–8 days.
GHRP-2
Growth Hormone / IGF-1 Axis
GHRP-2 is a synthetic hexapeptide growth hormone-releasing peptide that potently stimulates GH release from the pituitary gland.
GHRP-6
Growth Hormone / IGF-1 Axis
GHRP-6 is a synthetic hexapeptide growth hormone secretagogue and one of the original GHRPs studied.
Hexarelin
Growth Hormone / IGF-1 Axis
Hexarelin is a synthetic hexapeptide growth hormone secretagogue that produces the most potent GH release of any GHRP.
IGF-1 LR3
Growth Hormone / IGF-1 Axis
IGF-1 LR3 (Long R3 IGF-1) is a modified analog of insulin-like growth factor 1 featuring an arginine substitution at position 3 and a 13-amino acid N-terminal extension.